![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1529717
¹Ì±¹ÀÇ Ä«ÇÁ³ë±×·¡ÇÇ µð¹ÙÀ̽º ½ÃÀå ±Ô¸ð, Á¡À¯À² ¹× µ¿Ç⠺м® º¸°í¼ : Á¦Ç°º°, ¼Ö·ç¼Ç Á¦°ø¾÷üº°, ±â¼úº°, ±¸¼º¿ä¼Òº°, ¿ëµµº°, ÃÖÁ¾ ¿ëµµº°, ºÎ¹®º° ¿¹Ãø(2024-2030³â)U.S. Capnography Devices Market Size, Share & Trends Analysis Report By Product (Portable, Stationary), By Solution Offering (Integrated, Standalone), By Technology, By Component, By Application, By End Use, And Segment Forecasts, 2024 - 2030 |
Grand View Research, IncÀÇ ÃֽŠº¸°í¼¿¡ µû¸£¸é ¹Ì±¹ÀÇ Ä«ÇÁ³ë±×·¡ÇÇ µð¹ÙÀ̽º ½ÃÀå ±Ô¸ð´Â 2024-2030³â°£ 7.35%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)À» ³ªÅ¸³»¸ç 2030³â¿¡´Â 6¾ï 7,570¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
¿¹¸¦ µé¾î, COPD´Â ÇÕº´ÁõÀ» È¿°úÀûÀ¸·Î °ü¸®ÇÏ°í °¨ÁöÇϱâ À§ÇØ Áö¼ÓÀûÀ̰í Á¤È®ÇÑ È£Èí ¸ð´ÏÅ͸µÀÌ ÇÊ¿äÇϱ⠶§¹®¿¡ Ä«ÇÁ³ë±×·¡ÇÇ µð¹ÙÀ̽º¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡¸¦ ÁÖµµÇϰí ÀÖÀ¸¸ç, CDC¿¡ µû¸£¸é 2021³â¿¡´Â ¹Ì±¹ ¼ºÀÎ Áß ¾à 1,420¸¸ ¸íÀÌ COPD Áø´ÜÀ» ¹ÞÀ» °ÍÀ¸·Î ¿¹»óÇϰí ÀÖ½À´Ï´Ù. Ä«ÇÁ³ë±×·¡ÇÇ´Â COPD ȯÀÚÀÇ È£Èí°ï¶õÀ» Á¶±â¿¡ ¹ß°ßÇϰí Àû½Ã¿¡ °³ÀÔÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇÑ È¯±â »óŸ¦ ½Ç½Ã°£À¸·Î Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. µû¶ó¼ ȯÀÚÀÇ ¿¹Èĸ¦ °³¼±ÇÏ°í ¸ð´ÏÅ͸µ ±â´ÉÀ» °ÈÇØ¾ß ÇÑ´Ù´Â Çʿ伺ÀÌ ÀÓ»ó ÇöÀå¿¡¼ Ä«ÇÁ³ë±×·¡ÇÇ µð¹ÙÀ̽ºÀÇ Ã¤ÅÃÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù.
¶ÇÇÑ, Äڷγª19´Â ¹ÙÀÌ·¯½º °ü·Ã È£Èí±â ÇÕº´Áõ °ü¸®¿¡ ÀÖ¾î Á¤È®ÇÑ ½Ç½Ã°£ È£Èí ¸ð´ÏÅ͸µÀÇ Á߿伺À» °Á¶ÇÏ¸ç ¹Ì±¹ ³» Ä«ÇÁ³ë±×·¡ÇÇ µð¹ÙÀ̽º¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡¿¡ ±â¿©Çß½À´Ï´Ù. ÆÒµ¥¹ÍÀº ÀÔ¿ø ȯÀÚ¸¦ Áõ°¡½ÃÄ×°í, ƯÈ÷ ÀΰøÈ£Èí±â¸¦ »ç¿ëÇϰųª ½É°¢ÇÑ È£Èí±â ÁúȯÀ» ¾Î°í Àִ ȯÀÚ¿¡ ´ëÇÑ È¿°úÀûÀΠȯÀÚ ¸ð´ÏÅ͸µÀÇ Çʿ伺ÀÌ ³ô¾ÆÁ³½À´Ï´Ù. ÀÌ·¯ÇÑ È£Èí±â °ü¸® ¹× ¸ð´ÏÅ͸µ ±â´É °È¿¡ ´ëÇÑ ¼ö¿ä°¡ ±ÞÁõÇÏ¸é¼ Ä«ÇÁ³ë±×·¡ÇÇ µð¹ÙÀ̽º¿¡ ´ëÇÑ ¼ö¿ä°¡ Å©°Ô Áõ°¡ÇÏ¿© ½ÃÀå ÁøÃâ±â¾÷µé¿¡°Ô °æÁ¦Àû ÀÌÀÍÀ» °¡Á®´ÙÁÖ¾ú½À´Ï´Ù. ¿¹¸¦ µé¾î, ¸¶½Ã¸ð(Masimo)´Â 2018³â 8¾ï 2,990¸¸ ´Þ·¯¿¡¼ 2021³â 12¾ï 3,920¸¸ ´Þ·¯·Î Á¦Ç°º° ºÎ¹® ¸ÅÃâÀÌ Áõ°¡ÇÏ¿© 3³â°£ CAGR 14.3%¸¦ ¹Ý¿µÇß½À´Ï´Ù. ÀÌ·¯ÇÑ ¼ºÀåÀº ÇÙ½É Á¦Ç°ÀÎ SET »ê¼ÒÆ÷ȵµ ÃøÁ¤±âÀÇ °í°´ ±â¹Ý È®´ë, ³ë¸ð¶óÀÎ Ä«ÇÁ³ë±×·¡ÇÇ ¹× ·¹Àκ¸¿ì ÆÞ½º CO-¿Á½Ã¹ÌÅÍÀÇ ¸ÅÃâ Áõ°¡, OEM ÆÄÆ®³Ê È®´ë¿¡ ±âÀÎÇÕ´Ï´Ù.
¶ÇÇÑ, »ð°ü ȯÀÚ¿Í ºñ»ð°ü ȯÀÚ ¸ðµÎ¿¡¼ ¹«È£ÈíÀ» È¿°úÀûÀ¸·Î ÃøÁ¤ÇÏ°í ¿¬°ü½ÃŰ´Â µ¥ ÀÖ¾î Ä«ÇÁ³ë±×·¡Çǰ¡ Á¡Á¡ ´õ Áß¿äÇØÁö°í ÀÖ´Ù´Â ¿¬±¸ °á°úµµ ÀÖ½À´Ï´Ù. »õ·Î¿î ¿¬±¸¿¡¼´Â ¼Ò»ý¼ú¿¡ ´ëÇÑ ÀÌÇØ¸¦ ³ôÀ̱â À§ÇØ etCO2¿Í rSO2ÀÇ Á¶ÇÕÀ» ¿¬±¸Çϰí ÀÖ½À´Ï´Ù. ÀÌ ±â¼úÀº ÀÀ±Þ½Ç, º´¿ø Àü ȯ°æ, ¼Ò»ý ´ëÀÀÆÀ, ÁßȯÀÚ½Ç, óġ ÁøÁ¤, ÀÏ¹Ý Ä¡·á½Ç, ÅëÁõ °ü¸® µî ´Ù¾çÇÑ Ä¡·á °úÁ¤¿¡ Àû¿ëµÉ ¼ö ÀÖ´Â ±âȸ¸¦ Á¦°øÇÕ´Ï´Ù. ÀÓ»óÀǵéÀº °³º° ȯÀÚÀÇ »óŸ¦ ´õ Àß ÆÄ¾ÇÇϱâ À§ÇØ Ä«ÇÁ³ë±×·¡ÇǸ¦ Áö¼ÓÀûÀ¸·Î Ȱ¿ëÇϰí ÀÖÀ¸¸ç, ÀÌ´Â ¹Ì±¹ ½ÃÀåÀ» ÁÖµµÇϰí ÀÖ½À´Ï´Ù.
¶ÇÇÑ, ½ÃÀå ÁøÃâ±â¾÷µéÀº ¹Ì±¹ÀÇ Ä«ÇÁ³ë±×·¡ÇÇ µð¹ÙÀ̽º ½ÃÀå¿¡¼ ¼ºÀåÇϰí À¯ÁöÇϱâ À§ÇØ ´Ù¾çÇÑ ¼ºÀå Àü·«À» ÃßÁøÇϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, 2023³â 6¿ù Royal Philips¿Í Masimo´Â Philips IntelliVue MX850 ¹× MX750 Patient MonitorsÀÇ ±¹¼Ò »ê¼ÒÆ÷ȵµ ÃøÁ¤(O3)°ú SedLine Brain Function MonitoringÀÇ Çù·Â °ü°è¸¦ È®´ëÇß½À´Ï´Ù. ¸¦ ÅëÇØ ÀÓ»óÀǰ¡ Ãß°¡ÀûÀÎ ¸ð´ÏÅ͸µ Àåºñ ¾øÀ̵µ ½Å¼ÓÇϰí Á¤º¸¿¡ ÀÔ°¢ÇÑ ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖµµ·Ï µ½½À´Ï´Ù.
The U.S. capnography devices market size is expected to reach USD 675.7 million by 2030, registering a CAGR of 7.35% from 2024 to 2030, according to a new report by Grand View Research, Inc. For instance, COPD drives the rising demand for capnography devices due to the need for continuous and accurate respiratory monitoring to manage and detect complications effectively. According to the CDC, in 2021, approximately 14.2 million U.S. adults had physician-diagnosed COPD. Capnography offers real-time assessment of ventilation status, crucial for early detection of respiratory distress and timely intervention in COPD patients. Hence, the need for better patient outcome and enhanced monitoring capabilities are driving the adoption of capnography devices in clinical settings.
Furthermore, COVID-19 contributed to the rising demand for capnography devices in the U.S. by highlighting the critical need for accurate and real-time respiratory monitoring in managing respiratory complications associated with the virus. The pandemic increased hospitalizations and the necessity for effective patient monitoring, especially for those on ventilators or experiencing severe respiratory issues. This surge in demand for enhanced respiratory care and monitoring capabilities significantly boosted the demand for capnography devices benefitting the market players financially. For instance, Masimo increased its product specific segment revenue to USD 1,239.2 million in 2021 from USD 829.9 million in 2018, reflecting a three-year CAGR of 14.3%. This growth is attributed to the expansion of its core SET pulse oximeter customer base, higher revenues from NomoLine capnography and rainbow Pulse CO-Oximetry, and an expanding list of OEM partners.
Furthermore, research indicates that capnography is increasingly important for both intubated and non-intubated patients, as it effectively measures and links to apneic events. Emerging studies are also exploring the combination of etCO2 and rSO2 to enhance the understanding of resuscitation. The technology is expanding, offering opportunities for broader application across the continuum of care, including emergency departments, pre-hospital settings, resuscitation response teams, critical care units, procedural sedation, general care floors, and pain management. Clinicians continue to rely on capnography to gain better insights into individual patient conditions, thereby driving the market in the U.S.
Moreover, market players undertake various growth strategies to grow and sustain in the U.S. capnography devices market. For instance, in June 2023, Royal Philips and Masimo received FDA clearance to activate Regional Oximetry (O3), SedLine Brain Function Monitoring, and CO? measurements in Philips IntelliVue MX850 and MX750 Patient Monitors. This extension of their collaboration allows clinicians to make quick, informed decisions without needing additional monitoring equipment.